
Neurology® Podcast
American Academy of NeurologyAudio
- Format:
- Podcast
- New episodes:
- Several times a week
- Typical length:
- about 20 minutes
- Latest episode:
About this show
The Neurology Podcast provides practical information for neurologists and clinicians to practice the best possible medicine for patients. Examining methods and findings in peer-reviewed journals, the show provides insights that impact clinical practice and patient care. From the journal Neurology and the American Academy of Neurology, providing education and expert analysis since 2007.
Covers: neurology, clinical medicine, neurodegenerative disease, stroke, epilepsy, infectious disease, traumatic brain injury, health policy, medical education
Show details and episodes come from the publisher's public feed at rss.libsyn.com. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
This podcast from the American Academy of Neurology offers clinicians practical information drawn from peer-reviewed journals, mainly Neurology. Recent episodes cover Potosi virus as a human pathogen, pediatric brain injury from youth football, emergent stroke transfers, and physicians sharing personal experiences as patients.
Cosmos
Similar in subject
- Neurology Exam Prep Podcast
Both cover: epilepsy, clinical medicine, neurology - JAMA Clinical Reviews
Both cover: clinical medicine, neurology, infectious disease - Cram The Pance
Both cover: clinical medicine, infectious disease, medical education
Similar shows
Explore more
Episodes
From the Mailbox to the Microphone - Part 1
· 18 min
In part one of this series, Dr. Stacey Clardy talks with Drs. Jeff Ratliff, Andy Southerland, and Jason Crowell about the evolution of the Neurology® Podcast, from Ted Burns's founding vision to the conversations and formats that have connected with listeners for nearly two decades. Read the related article in Neurology®. Nominations for the 2027 Ted M. Burns Humanism in Neurology Award will be open until December 18, 2026, at 3:00 pm CT. Disclosures can be found at Neurology.org (https://www.neurology.org/).
Not rated yetEstablishing Potosi Virus as a Human Pathogen - Part 2
· 13 min
In the second episode of this two-part series, Dr. Stacey Clardy talks with Dr. Justin Abbatemarco about the risks of immunosuppression for autoimmune neurologic diseases and how to optimize the benefits of immunotherapies while minimizing the associated risks. Read the related article in Neurology®. Disclosures can be found at Neurology.org.
Not rated yetEstablishing Potosi Virus as a Human Pathogen - Part 1
· 19 min
In part one of this two-part series, Dr. Stacey Clardy talks with Dr. Justin Abbatemarco about why infection can be overlooked in people on anti-CD20 therapy and practical ways clinicians can improve testing, prevention, vaccination, and collaboration with laboratories and infectious disease specialists. Read the related article in Neurology®. Disclosures can be found at Neurology.org.
Not rated yetPhysicians as Patients: A Live On-stage Discussion
· 25 min
In this special conversation, recorded live at this year's AAN Annual Meeting, Dr. Alison Christy talks with Drs. Franziska Herpich and Yolanda Holler-Managan about how personal experiences with stroke, disability, and caregiving have changed the way they understand and care for patients and families. Listen to the previous episode featuring Dr. Franziska Herpich. Disclosures can be found at Neurology.org (https://www.neurology.org/).
Not rated yetYouth Football and the Epidemic of Pediatric Brain Injury
· 15 min
Dr. Dara Albert talks with Isaac Thorman about football-related traumatic brain injury in children and young adults and its association with later neurologic and psychiatric outcomes. Read the related article in Neurology® Clinical Practice. Disclosures can be found at Neurology.org (https://www.neurology.org/).
Not rated yetNovember 2026 Recall: Updates in Neurodegenerative Disease: Diagnosis, Treatment, and Prevention
· 1 hr 10 min
The November 2026 Recall features four previously published episodes on updates in neurodegenerative disease diagnosis, treatment, and prevention. The episode begins with a two-part discussion with Drs. Trey Bateman and Gregg Day discussing highlights from the 2026 Alzheimer's Association International Conference. The episode continues with Drs. Sonia Vallabh and Eric Minikel discussing the future of prion disease treatment. The episode concludes with Dr. Pascal Geldsetzer discussing how the herpes zoster vaccination may have neuroprotective effects, potentially delaying or preventing dementia. Podcast links: 2026 Alzheimer's Association International Conference Reports - Part 1 2026 Alzheimer's Association International Conference Reports - Part 2 (https://directory.libsyn.com/episode/index/id/42580370) Prion Disease Clinical Trial NN112 (https://directory.libsyn.com/episode/index/id/41458975) Herpes Zoster Vaccination and Incident Dementia in Canada (https://directory.libsyn.com/episode/index/id/43316914) Article links: PrP-targeting siRNA Safety & Mechanism Study (https://clinicaltrials.gov/study/NCT07444580) Herpes Zoster Vaccination and Incident Dementia in Canada Disclosures can be found at Neurology.org.
Not rated yetTrends in Emergent Interfacility Ischemic Stroke Transfers
· 15 min
Dr. Andy Southerland talks with Dr. Matthew Gusler about trends in emergent interfacility transfers for ischemic stroke and factors associated with transfer for care. Read the related article in Neurology®. Disclosures can be found at Neurology.org.
Not rated yetClinical Reasoning: Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia in a Patient With MS
· 25 min
Dr. Zohaib Siddiqi talks with Dr. Michel Toledano about the diagnosis and management of infectious rhombencephalitis in patients receiving immunomodulatory therapy. Read the related Resident & Fellow Section article in Neurology®. Disclosures can be found at Neurology.org (https://www.neurology.org/).
Not rated yetIncidence and Prevalence of Conversions to MCI and Dementia in Patients With Essential Tremor
· 13 min
Dr. Matthew Barrett talks with Dr. Elan Louis about the incidence and prevalence of mild cognitive impairment and dementia in essential tremor and what these findings may mean for patient care and future research. Read the related article in Neurology®. Disclosures can be found at Neurology.org.
Not rated yetThe Menopause Transition and Epilepsy
· 20 min
Dr. Katie Krulisky talks with Dr. Kelsey Smith about the impact of menopause on women with epilepsy, including therapeutics and clinical management during midlife. Read the related article in Neurology®Clinical Practice. Disclosures can be found at Neurology.org. Podcast Transcript: Dr. Jose Merino: This is Jose Merino, Editor-in-Chief of the Neurology Family of Journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening and have a great week. Dr. Katie Krulisky: Hello, and welcome to this episode of the Neurology Podcast. This is Katie Kruliski from the VA and University of Utah in Salt Lake City, Utah. Today, I have the pleasure of talking with Kelsey Smith. She's a neurologist and epileptologist at Mayo Clinic in Rochester, Minnesota. We will be discussing her recent paper published in the Neurology Clinical Practice Journal titled The Menopause Transition and Epilepsy: A Focus on Therapeutics. Welcome, Kelsey, and thank you for joining us. Dr. Kelsey Smith: Thank you so much for having me. I'm really excited to be here today to talk about this paper and this really important topic. Dr. Katie Krulisky: Yes. Your paper highlighted a staggering statistic, that women spend approximately 40% of their lives post-menopause. That shook me when I was reading this for a presentation on management of women in epilepsy. Being a woman, I felt totally blindsided by the statistic. I've never thought about it this way. I feel like so much of the emphasis of our clinical practice in epilepsy is choosing the right medications for pregnancy. And there is a lack of information and focus on women in perimenopause and post-menopause, even though a much larger percentage of the lifespan is spent in this phase. Let's go ahead and start with the clinical scenario. A 45-year-old woman with focal epilepsy is having some symptoms attributed to perimenopause and is interested in pursuing hormonal treatments. As her epileptologist, what is your approach to counseling her based on the current available data? Dr. Kelsey Smith: And when it comes to patients like this, it's a very important topic. And the first thing is that it really requires both an individualized and multidisciplinary approach. So I think first as an epileptologist, I want to understand all I can about her epilepsy, what the current seizure control is, what the current therapy is, what the epilepsy's been like over other life stages if she's had epilepsy no earlier, to understand how seizures may have been during menstrual cycles to know if there's kind of a hormonal driver of seizures that's been noticed through the lifespan. And then also I really want to understand about her menopause symptoms. What are the symptoms that are really bothering her that she's hoping to start the hormonal therapy for? And are those symptoms things like vasomotor symptoms or sleep disturbances? And are those actually also influencing her current seizure control? If the vasomotor symptoms are waking her up at night and she's not getting good rest, is this lowering the seizure threshold and actually driving worse seizure control? Understanding all of this background's really important. And then to discuss with her what the data is about menopausal hormonal therapy and how it's related to epilepsy, how that data is really limited. And so we don't have a lot of data to go off of to provide counseling in this scenario. And all the studies that have really looked at this topic are really quite old, over 20 years old and have not used the same formulations of menopause hormonal therapy we use nowadays. And a lot of these studies didn't even use the anti-seizure medicines that we use nowadays. It's important to work with a patient like this and really let her know that despite the limited data, that epilepsy itself should not be a strict contraindication to considering menopausal hormonal…
Not rated yetHerpes Zoster Vaccination and Incident Dementia in Canada
· 15 min
Dr. Margarita Fedorova talks with Dr. Pascal Geldsetzer about how the herpes zoster vaccination may have neuroprotective effects, potentially delaying or preventing dementia. Read the related article in The Lancet Neurology. Disclosures can be found at Neurology.org. Podcast Transcript: Dr. José Merino: This is José Merino, editor-in-chief of the Neurology Family of Journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening and have a great week. Dr. Margarita Fedorova: Hi, this is Margarita Fedorova and I'm a neurology resident at the Cleveland Clinic. Today, we're exploring a study that speaks to an idea that's been building for a few years now, that vaccination itself might be neuroprotective. I'm here with Pascal Geldsetzer, a physician and epidemiologist at Stanford University. Pascal is the author on a paper published in the February 2026 issue of Lancet Neurology titled "Herpes Zoster Vaccination and Incident Dementia in Canada: An Analysis of Natural Experiments." What makes the study different is how they got at the question. When Ontario started publicly funding the shingles vaccine, eligibility came down almost entirely to date of birth. People born a few weeks on one side of a cutoff could get the vaccine for free, and people born a few weeks on the other side could not. That left Pascal and his colleagues with two groups of older adults who should be alike in essentially every way, except their access to the vaccine. And they asked whether those groups went on to develop dementia in different rates. We wanted to bring Pascal to the podcast because this is a question our patients are already asking us in clinic, and because vaccination is one of the few things we can offer an older adult that might actually protect the brain. Pascal, welcome to the podcast. Dr. Pascal Geldsetzer: Thank you very much for having me. Dr. Margarita Fedorova: Let's start with a take-home message. If I'm rounding with a team tomorrow and I get to teach them one thing from your paper, one thing I want them to still remember six months from now, what should that be? Dr. Pascal Geldsetzer: I think it is that for shingles vaccination and dementia, we now have a body of evidence from observational data that we're usually never able to obtain in terms of the fact that we are able to get at cause and effect in a much more plausible way than we are usually able to. And we can say here now that shingles vaccination may well have a delaying or preventing effect on the dementia disease process. Dr. Margarita Fedorova: Before we get into your study, give us the background. We tend to think about dementia in terms of amyloid, tau, vascular risk, and lifestyle. Where do vaccines come into it? And is this really a shingles story or is it something broader about vaccination and brain health in older adults? Dr. Pascal Geldsetzer: Yeah, so unfortunately we don't know exactly. And so of course, broadly speaking, it could be either through reducing reactivations of the chickenpox virus or varicella zoster virus, which we know is a neurotropic virus, which we know reactivates throughout life. And so reducing these reactivations and probably accompanying neuroinflammatory processes may well have benefits. But there may also be a broader potentially virus-independent immune mechanism at play here that may also apply to other vaccines than just shingles vaccination. So we don't really understand the mechanism yet. It's a very interesting and fascinating area of research and hopefully we'll learn more in the future. Dr. Margarita Fedorova: We already knew from a lot of prior work that shingles vaccine was associated with a lower risk of dementia, but in the paper you were direct that those earlier studies can't really speak to cause and effect, and that's a really big part of why this one matters. What goes wrong when we simply compare…
Not rated yetUnderstanding the Forces Shaping US Health Care
· 21 min
Dr. Jason Crowell talks with Dr. John McDonough about the historical and economic factors shaping the US healthcare system and why understanding these systemic forces matters for neurologists and patient care. Read the related article in The Harvard Gazette. Disclosures can be found at Neurology.org. Podcast Transcript: Dr. Jose Merino: This is Jose Merino, Editor-in-Chief of the Neurology Family of Journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening and have a great week. Dr. Jason Crowell: Hey, this is Jason Crowell from Norton Neuroscience Institute in Louisville, Kentucky. Thanks for listening to today's Neurology Podcast. Most of our audience members are practicing neurologists, you're in training or you're in an academic setting or in private practice. And for those of us who are in practice, we are well aware of the challenges of helping our patients access drugs, getting prior authorizations approved, the other areas of friction that exist in our healthcare system. And I would say that whether we realize it or not, these areas of friction are symptoms of larger choices about how our hospitals and clinics operate. And so to help us think about these things, today we've invited John McDonough to join us. John is a professor of public health practice at the Harvard T.H. Chan School of Public Health. We recently read an article about John's work published August 18th, 2026 in the Harvard Gazette and wanted to invite him to join us today. So John, thank you so much for your time. Dr. John McDonough: Pleasure to be here with you, Jason. Thanks for inviting me. Dr. Jason Crowell: So John, in this piece that I read in the Harvard Gazette that was describing some of the work you've done, you point to a specific historical pivot around 1980 when US healthcare spending grew at a pace that's disconnected from the rest of the industrialized world. And that was 40 to 50 years ago, so most of our audience does not have experience with the practice of medicine prior to that time. The title of your upcoming book is America's Wrong Turn: US Healthcare in the Neoliberal Era. Can you help summarize what you mean by this wrong turn that happened? And also, can you just give us some background about what you mean by this neoliberal era? Dr. John McDonough: So I've been influenced by a Yale political scientist, Stephen Skowronek, who suggests that there's a helpful way to look at American political economic history, not through the lens of individual presidential terms like say the Nixon era or the Reagan era or the Obama era, but to look at larger multi-decade politico economic eras where there are dominant political strains. And Skowronek says we've had five of these eras over the 250 years. But just to talk about the two most modern ones that are most relevant to our discussion here. The first one started in 1933 with Franklin Delano Roosevelt's inauguration as president in the midst of the Great Depression. And inaugurating an era that became known as the New Deal era, which was an era of muscular federal and state governmental leadership and guidance in terms of steering the economy toward greater productivity, toward higher wages, toward all different kinds of innovations like social security and Medicare and Medicaid. That era didn't end when FDR died. It went on until 1980 when it collapsed in the end of the Jimmy Carter presidency with upset and anger over what was then called stagflation, the Iran hostage crisis, the gas crisis from the Middle East with OPEC. So it was succeeded in 1980 with the inauguration of Ronald Reagan. And Ronald Reagan came in openly talking about let's move away from the New Deal era. It's not working anymore. We have to go forward. And that era was in some ways, people call it the neoliberal era because it was an era defined by a set of economists like Milton Friedman,…
Not rated yetPrevalence of CTE at Death in National Football League Players
· 25 min
Dr. Shuvro Roy talks with Dr. Daniel Daneshvar about the prevalence of CTE at death among NFL players and the association between CTE severity and the risk of dementia. Read the related article in the BMJ. Disclosures can be found at Neurology.org. Podcast Transcript: Dr. Jose Merino: This is Jose Merino, Editor-in-Chief of the Neurology family of journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening, and have a great week. Dr. Shuvro Roy: Hi, this is Shuvro Roy from the University of Washington, and welcome to today's Neurology Podcast. We'll be covering a study titled Prevalence of Chronic Traumatic Encephalopathy and Death in National Football League Players: A Retrospective Population-Based Cohort Study from 2008 to 2001, published in BMJ. We're joined by lead author Daniel Daneshvar, Chair of Spaulding Rehabilitation at Harvard Medical School. Dan, thanks for joining us. Dr. Daniel Daneshvar: Great to be here. Thanks for having me. Dr. Shuvro Roy: So Dan, this study has already received widespread national attention, but please give us the headline. What did you find and what's the number one thing that you want listeners to remember? Dr. Daniel Daneshvar: So this was a study looking at how commonly this specific neurodegenerative disease called chronic traumatic encephalopathy or CTE, how commonly this occurs in a cohort with a lot of repeated traumatic brain injury exposure, namely former National Football League professional football players. And what we found was that between the years of 2016 and 2021, so for that five-year period, the absolute minimum prevalence of CTE at death in this group was 25%. The absolute maximum was 98%, and the true rate is somewhere in that range. Now, for context, in the general population in community cohort studies, the prevalence of this pathology is somewhere south of 1%. Dr. Shuvro Roy: And what does this study add to our current understanding of CTE and neurologic disease associated with head trauma? Dr. Daniel Daneshvar: So we've long known that individuals who have experienced repeated traumatic brain injury exposure, whether through sports like NFL, NHL players, professional soccer players, whether through occupational exposures like in the military or as in individuals who experience intimate partner violence, we've long known that these individuals have higher rates of neurodegenerative disease. But what we haven't known is just how much higher that rate is. And what this study has shown us is first off that this is alarmingly high in former professional football players at death. And then the second thing that this study shows us is that this pathology is unsurprisingly very linked to clinical symptoms, including with more severe disease, cognitive impairment that's so severe it results in dementia, meaning impairment in someone's ability to perform activities of daily living, including feeding, bathing, dressing, grooming, toileting, those kinds of things. Dr. Shuvro Roy: As you pointed out, your primary finding was that there was this maximum versus minimum prevalence, which ranged from anywhere from 98% to 25%, so obviously a wide range. But to help us understand this study, can you walk us through that methodology, the minimum and maximum prevalence approach? Why a range rather than a single estimate? And you mentioned that the number is likely somewhere in between. Where do you think that true number sits, if we even can estimate? Dr. Daniel Daneshvar: So to understand why there's a range, it's helpful to understand how we got to these numbers. And so when we looked at the individuals who had CTE who played in the NFL across three brain banks, mostly the BU CTE Center, but also the Mount Sinai Brain Bank and the UCSF Alzheimer's Disease Center Brain Bank, when we combined all NFL players across these brain banks, we found that NFL players…
Not rated yetClinical Manifestations of Primary CNS T Cell Lymphoma
· 14 min
Dr. Kait Nevel talks with Dr. Katharina Schmidbauer about primary CNS T-cell lymphoma, highlighting diagnostic challenges, imaging characteristics, and treatment approaches for this rare disease. Read the related article in Neurology®. Disclosures can be found at Neurology.org. Podcast Transcript: Dr. José Merino: This is José Merino, editor-in-chief of the Neurology Family of Journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening and have a great week. Dr. Kait Nevel: Hello, my name is Kait Nevel. Today, I am interviewing Katharina Schmidbauer on her article, "Clinical Manifestations of Primary CNS T-Cell Lymphoma." Welcome to the Neurology Podcast. And Katharina, I would love to hear a little bit about you. Dr. Katharina Schmidbauer: Thank you, Kait. Thank you for having me. It's a pleasure. I am a neurologist with a great research interest in neuro-oncology, working at the University Hospital of Munich. Dr. Kait Nevel: Wonderful. Thank you for that. What do you think the most important takeaway is from your article for the practicing neurologist? Dr. Katharina Schmidbauer: Primary CNS T-cell lymphoma is very rare and the diagnosis is often really difficult to establish. In this study, we present hallmarks of the disease that could help with the diagnosis in the future. And our case series really illustrates many diagnostic challenges. The first important message would be how to deal with diagnostic uncertainty. If you have a progressive tumefactive CNS lesion and the clinical course, the imaging, and pathology don't quite fit together, CNS lymphoma and also T-cell CNS lymphoma need to remain on the differential, even if the first biopsy is inconclusive. And in this context, it's also important to avoid, of course, steroids before biopsy because they could cause regression of the lesion and therefore make the biopsy non-diagnostic, which is not the same as a negative biopsy. Dr. Kait Nevel: Thank you for that. And before we get into some more of the details of the findings of your study, could you give us a brief overview of the background and methods of your study? Dr. Katharina Schmidbauer: Sure. Primary CNS T-cell lymphoma is very rare and an aggressive subtype of CNS lymphoma. Most primary CNS lymphomas are B-cell lymphomas, but for T-cell lymphoma, we have very little systematic data. In fact, there are only three case series so far, and therefore we performed a multicenter retrospective study across three centers in Munich, Heidelberg, and Boston. And there we identified 16 adult patients with histologically confirmed primary CNS T-cell lymphoma without systemic disease treated between 2008 and '24. We looked at several levels of the disease, the clinical presentation, of course, histopathology, immunophenotype, T-cell receptor gene rearrangement testing, and if available, next-generation sequencing. And we also gathered MRI and PET imaging, treatment regimes, and of course outcome data. We also centrally reviewed the imaging and histopathology results in a multidisciplinary setting. And the study is mainly of course descriptive. However, we also tried to find associations that are relevant for outcome. Dr. Kait Nevel: Getting into some of the things that you found or discovered through this study, what's one thing that surprised you? Dr. Katharina Schmidbauer: One surprising finding of the study was the heterogeneous presentation on MRI and the high number of misdiagnosis on MRI in more than half of the patients. If you look into the imaging figures in the paper, these tumors can present as like any other disease. They can mimic neuroinflammatory disease, high-grade glioma, small vessel disease, and even meningioma or leptomeningeal disease. So the most common misdiagnosis was high-grade glioma, and indeed these lesions often showed very infiltrative growth patterns and almost streaky or…
Not rated yetOctober 2026 Recall: Updates in Immune-Based Therapies for Neurologic Disease
· 1 hr 4 min
The October Recall features four previously posted episodes on immune‑based therapies for neurologic disease. In the first episode, Dr. Bhaskar Roy reviews the latest treatments, comparing their efficacy and safety. The second episode, with Dr. Michael Levy, focuses on satralizumab for treating relapsing MOGAD, current management challenges, and the encouraging results of this new therapy. That conversation leads into an episode with Dr. Amanda L. Piquet, who discusses the efficacy and safety of miv-cel in patients with stiff person syndrome. The episode concludes with Dr. Irene Cortese highlighting recent advances in the treatment of PML. Podcast links: Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments (https://directory.libsyn.com/episode/index/id/42767330) Safety and Efficacy of Satralizumab in Patients with Relapsing MOGAD (https://directory.libsyn.com/episode/index/id/41730250) Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome (https://directory.libsyn.com/episode/index/id/41579305) Resolution of PML after Treatment with Virus-Specific T Cells and HCT (https://directory.libsyn.com/episode/index/id/43022608) Article links: Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments Safety and Efficacy of Satralizumab in Patients with Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8) Resolution of PML after Treatment with Virus-Specific T Cells and HCT (https://www.nejm.org/doi/full/10.1056/NEJMc2514186) Disclosures can be found at Neurology.org.
Not rated yetThe Future of Child Neurology Residency Training
· 21 min
Dr. Dara Albert talks with Dr. Bruce Cohen about the future of child neurology residency training, exploring current models, consensus areas, and challenges in evolving the curriculum to meet future healthcare needs. Read the related article in Neurology® Education. Disclosures can be found at Neurology.org. Podcast Transcript: Dr. Jose Merino: This is Jose Merino, editor-in-chief of the Neurology Family of Journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening and have a great week. Dr. Dara Albert talks with Dr. Bruce Cohen: Hi, this is Dara Albert from Nationwide Children's Hospital and Ohio State University. I am delighted to be joined today by fellow Ohioan, Bruce Cohen, a child neurologist at Akron Children's Hospital and an expert in the care of children and adults with mitochondrial disorders. Bruce is the lead author of a paper published in June 2026 called Education Research: The Future of Child Neurology Residency Training: The Perspective of a Child Neurology Society Task Force. Child neurology occupies this unique space at the intersection between pediatrics and adult neurology and pediatric neurology. And really there are a few topics in our field that generate as much discussion amongst child neurologists as how we should train the next generation. You get 10 child neurologists in the room, maybe there's 15 different opinions on how we should do this. Recognizing that there's a lot of evolution in our field, the Child Neurology Society, or CNS as I'm going to refer to it, assembled a task force to explore whether the current training models continue to meet the needs of our trainees, practicing physicians, and the patients that they serve. And we're going to talk about the results of that task force and what was published in the paper. Before we dive into that though, I do want to note that Bruce is joining us today as a representative of the task force and its findings. And while he contributed to this work, the perspectives and recommendations outlined in the paper are going to reflect the collective views of the task force and may not always fully align with his individual opinions. So Bruce, welcome to the podcast. Dr. Bruce Cohen: Thanks. It's great to be here. Dr. Dara Albert talks with Dr. Bruce Cohen: Absolutely. Let's start with a little history. Many may not be as familiar with how child neurology training developed in the United States. Can you tell us a little bit more about the current training model, how it came to be, and how it has evolved over the decades? Dr. Bruce Cohen: The current training model is about 50 years old. 50 years ago, there was no CAT scans or MRI scans or genetic testing. We had pneumoencephalograms. So there really have been major changes in the last 50 years in how we take care of children with neurological problems and how we treat them. And one would expect that the training needs would change as well over that timeframe. So here we are today to discuss the differences of opinions among my colleagues. Dr. Dara Albert talks with Dr. Bruce Cohen: It's hard to imagine doing an encephalogram these days. We've come a long way from that. Dr. Bruce Cohen: Well, it just shows my age. I remember taking tours of medical school, seeing the pneumoencephalogram suite. It was still up and running when I was in training. It doesn't seem that long ago. It was in the 1980s, but they still had the chair. Dr. Dara Albert talks with Dr. Bruce Cohen: Wow. Why did the Child Neurology Society or CNS feel that this task force was needed at this particular moment? What questions or challenges were you hoping to address? Dr. Bruce Cohen: So we know the ACGME is going to go on their 10-year cycle and look into the training requirements of child neurology in 2027. They're getting set up to do that. And it was just seemingly an appropriate time at the end of my term as…
Not rated yetPharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations
· 22 min
Dr. Tesha Monteith talks with Dr. Tamara Pringsheim about the updated American Academy of Neurology (AAN) and American Headache Society (AHS) guidelines on pharmacologic treatment for migraine prevention in adults. Read the related article in Neurology®. Disclosures can be found at Neurology.org. Show transcript: Dr. Jose Merino (00:08): This is Jose Merino, editor-in-chief of the Neurology Family of Journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening and have a great week. Dr. Tesha Monteith (00:23): Hi, this is Tesha Monteith with the Neurology Podcast. I'm excited to talk to you today about the update in Migraine Guideline: Pharmacologic Treatment for Migraine Prevention in Adults: Practice Guideline Recommendations, a report of the American Academy Neurology Guidelines Subcommittee, and the American Headache Society. Since the last guideline in 2012, there's been a lot of new advances, including the introduction of CGRP inhibitors for acute and preventive treatment. (00:53): With me to discuss is the lead author, Tamara Pringsheim, a neurologist at the Department of Clinical Neurosciences, Psychiatry, Pediatrics, and Community Health Sciences at the University of Calgary. How are you, Tamara? Dr. Tamara Pringsheim (01:06): Great. Thank you for asking me to talk to you about this. Dr. Tesha Monteith (01:09): Why don't you tell me a little bit about yourself and how you got involved in this work? Dr. Tamara Pringsheim (01:14): Sure. I've been working as a methodologist for the American Academy of Neurology Guidelines Subcommittee for a number of years, since 2015. Prior to that, I was a member of the guideline development subcommittee from 2011. I've worked on a number of different guidelines across neurological conditions. Dr. Tesha Monteith (01:36): Great. So how do these new guidelines compare, just broadly speaking, with the older guidelines? Dr. Tamara Pringsheim (01:43): I guess since the last guidelines were published more than 10 years ago, we've had changes to our methodological process. We had a major update to our guideline process manual in 2017, and guideline methodology has continued to evolve over that time period. And as well, a number of targeted treatments for migraine have come out. So there's been an explosion of evidence, particularly in the last five to seven years. And so we have a whole new class of medications available for migraine prevention, which really target our underlying understanding of the condition, whereas most of the other medications were discovered through serendipity. Dr. Tesha Monteith (02:33): So I know that you reviewed over 200 randomized controlled trials. And so how was the quality or confidence of the evidence determined? Dr. Tamara Pringsheim (02:47): With our process, we start by rating risk of bias for every article. This basically gets at a number of different features related to the clinical trial methodology and reporting, and it helps us determine how confident we are in the evidence. In order for us to be highly confident that the results that we are seeing reflect the truth, we typically need to have at least two Class 1 studies for any intervention outcome pair. The effect size estimate also has to meet a certain threshold in terms of the effect size and the precision surrounding that estimate. So if we feel that based on what the panel decides in terms of what is the minimal clinically important difference between an intervention and placebo, that will help us determine our confidence in the evidence. (03:51): So there's this critical coming together of the number of studies, the quality of studies, the effect size, and the precision of the evidence that helps us determine our confidence in the evidence. And all of this is done behind the scenes using a very algorithmic approach so that these rules are faithfully applied across the…
Not rated yetResolution of PML after Treatment with Virus-Specific T Cells and HCT
· 21 min
Dr. Justin Abbatemarco talks with Dr. Irene Cortese about recent advances in the treatment of progressive multifocal leukoencephalopathy (PML), focusing on immune-based therapies like virus-specific T cells and immune checkpoint inhibitors. Read the related article in The New England Journal of Medicine. Disclosures can be found at Neurology.org. Show transcript: Dr. José Merino: This is José Merino, editor-in-chief of the Neurology Family of Journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening, and have a great week. Dr. Justin Abbatemarco: Hello and welcome. This is Justin Abbatemarco with the Cleveland Clinic here with Irene Cortese to discuss an update on progressive multifocal leukoencephalopathy treatment in light of a New England Journal of Medicine correspondence, Resolution of PML After Treatment with Virus-Specific T Cells and HCT. Irene directs the Experimental Immunotherapeutics Unit at NINDS. Hello and welcome. Dr. Irene Cortese: Hi, thank you for the invitation to join you today. Dr. Justin Abbatemarco: It's a pleasure to have you on and to talk about this expanding space in rare disease. And maybe if we could start off, can we just take an overview on how PML usually presents and why does it remain so difficult to treat? Dr. Irene Cortese: PML, or progressive multifocal leukoencephalopathy, is an opportunistic infection of the brain that is caused by the JC virus. And most of us carry this virus lifelong and without any symptoms, and it really only causes disease when the immune system is significantly compromised and loses the ability to keep it in check. And so when that happens, the virus can gain the ability to infect oligodendrocytes, and this can lead to the rapidly progressive demyelinating infection called PML. These lesions that develop in PML are typically located in the white matter, and they are most often multifocal. And this leads to the clinical manifestation of a combination of cortical and subcortical symptoms that evolve over weeks to months. And, unfortunately, if immune competence can't be restored quickly, then the disease is fatal within just a few months. And so that's really the core of the problem here, is that there is no effective direct antiviral treatment. And the only thing that works is restoring the immune system ability to control it, but that's often very difficult to do. When it's even possible, it's frequently just not even fast enough. And so you can see this even in situations where you'd think that we'd have an advantage, for example, in HIV-associated PML, where we do have effective antiretroviral therapy. Even there, restoring immune competence can sometimes just take too long relative to how quickly PML progresses. And so on top of all that, PML is really quite rare and is also remarkably heterogeneous because it can occur in very different patient populations from HIV to hematological malignancy to genetic immune deficiencies. And this rarity and heterogeneity really make both the diagnosis difficult and also treatment development quite difficult. Dr. Justin Abbatemarco: It's such a interesting story, and these different backgrounds really present different challenges. But at these last few years, this has been a success story in some way because we've seen so much effort and research into this rare disease space, which is encouraging. We mentioned this at the top, but there are immune checkpoint inhibitors that have at least been trialed for this T cell exhaustion to see if we can boost the immune system, and then more recently with your work around allogeneic-specific T cells to help clear the infection. What have you taken away from those updates? Dr. Irene Cortese: The biggest takeaway is that these two approaches, checkpoint inhibitors and Virus-Specific T Cells, have really transformed the way that we think about PML. So for decades,…
Not rated yetPrimary Motor Cortex Involvement and Seizure Risk in Patients With Brain Metastases
· 13 min
Dr. Kait Nevel talks with Drs. Ayal Aizer and Clara Baselga-Garriga about the link between primary motor cortex involvement in brain metastases and increased seizure risk, highlighting implications for patient management and future research directions. Read the related article in Neurology®. Disclosures can be found at Neurology.org.
Not rated yetMarijuana Rescheduling: What It Means for Neurology Research and Care
· 27 min
Dr. John Ney talks with Dr. Daniele Piomelli about the evolving role of cannabis in neurology, exploring its history, current research, and potential future applications. Read the related article in The New England Journal of Medicine. Disclosures can be found at Neurology.org.
Not rated yet